| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rheumatology | 18 | 2022 | 46 | 7.290 |
Why?
|
| Arthritis, Rheumatoid | 17 | 2022 | 155 | 3.450 |
Why?
|
| Osteoporosis | 7 | 2022 | 88 | 2.940 |
Why?
|
| Bone Density Conservation Agents | 7 | 2022 | 43 | 2.520 |
Why?
|
| Rheumatologists | 6 | 2021 | 14 | 2.480 |
Why?
|
| Education, Medical, Graduate | 7 | 2022 | 214 | 2.440 |
Why?
|
| Scleroderma, Systemic | 21 | 2018 | 446 | 1.790 |
Why?
|
| Fellowships and Scholarships | 6 | 2021 | 127 | 1.660 |
Why?
|
| Osteoporotic Fractures | 2 | 2022 | 9 | 1.410 |
Why?
|
| Diphosphonates | 3 | 2018 | 39 | 1.280 |
Why?
|
| Clinical Competence | 7 | 2022 | 657 | 1.280 |
Why?
|
| Antirheumatic Agents | 8 | 2022 | 58 | 1.270 |
Why?
|
| Curriculum | 10 | 2022 | 575 | 1.170 |
Why?
|
| Hypertension, Pulmonary | 10 | 2018 | 232 | 1.100 |
Why?
|
| Internship and Residency | 4 | 2022 | 596 | 1.080 |
Why?
|
| Humans | 76 | 2022 | 68525 | 0.850 |
Why?
|
| Health Services Needs and Demand | 2 | 2020 | 149 | 0.840 |
Why?
|
| Orthopedics | 1 | 2022 | 88 | 0.820 |
Why?
|
| Pandemics | 2 | 2022 | 346 | 0.810 |
Why?
|
| Glucocorticoids | 4 | 2022 | 222 | 0.800 |
Why?
|
| Internal Medicine | 2 | 2022 | 118 | 0.760 |
Why?
|
| Faculty, Medical | 2 | 2020 | 110 | 0.670 |
Why?
|
| Musculoskeletal Pain | 1 | 2018 | 7 | 0.670 |
Why?
|
| Bone Density | 2 | 2017 | 159 | 0.660 |
Why?
|
| Fractures, Stress | 2 | 2015 | 12 | 0.650 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 807 | 0.640 |
Why?
|
| Pain Threshold | 5 | 2022 | 55 | 0.640 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 136 | 0.630 |
Why?
|
| Telemedicine | 2 | 2022 | 699 | 0.570 |
Why?
|
| Aromatase Inhibitors | 1 | 2016 | 17 | 0.560 |
Why?
|
| Autoimmune Diseases | 2 | 2016 | 186 | 0.560 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2016 | 186 | 0.550 |
Why?
|
| Central Nervous System Sensitization | 3 | 2020 | 8 | 0.550 |
Why?
|
| Rheumatic Diseases | 1 | 2016 | 35 | 0.550 |
Why?
|
| Lung Diseases | 4 | 2021 | 175 | 0.540 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2015 | 1 | 0.540 |
Why?
|
| Denosumab | 1 | 2015 | 2 | 0.540 |
Why?
|
| Symptom Assessment | 1 | 2015 | 33 | 0.530 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 91 | 0.520 |
Why?
|
| Checklist | 1 | 2015 | 76 | 0.500 |
Why?
|
| Tibia | 1 | 2015 | 93 | 0.500 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 100 | 0.500 |
Why?
|
| Consensus | 1 | 2015 | 211 | 0.500 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 510 | 0.490 |
Why?
|
| Anticonvulsants | 1 | 2016 | 223 | 0.490 |
Why?
|
| Preventive Health Services | 1 | 2014 | 86 | 0.480 |
Why?
|
| Fasciitis | 2 | 2009 | 30 | 0.480 |
Why?
|
| Referral and Consultation | 1 | 2016 | 383 | 0.470 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 188 | 0.470 |
Why?
|
| Eosinophilia | 2 | 2009 | 47 | 0.470 |
Why?
|
| Teaching | 1 | 2015 | 169 | 0.470 |
Why?
|
| Fibromyalgia | 2 | 2022 | 29 | 0.420 |
Why?
|
| Lung Diseases, Interstitial | 4 | 2014 | 110 | 0.420 |
Why?
|
| Arthralgia | 3 | 2022 | 30 | 0.400 |
Why?
|
| Physician Assistants | 3 | 2019 | 47 | 0.380 |
Why?
|
| Nurse Practitioners | 3 | 2019 | 90 | 0.370 |
Why?
|
| Vertebroplasty | 1 | 2010 | 16 | 0.370 |
Why?
|
| Pain Measurement | 7 | 2022 | 328 | 0.350 |
Why?
|
| Middle Aged | 31 | 2021 | 21119 | 0.340 |
Why?
|
| Pain | 4 | 2022 | 472 | 0.330 |
Why?
|
| Adult | 23 | 2022 | 21375 | 0.330 |
Why?
|
| Inpatients | 2 | 2022 | 208 | 0.320 |
Why?
|
| Pulmonary Fibrosis | 6 | 2012 | 157 | 0.320 |
Why?
|
| Cyclophosphamide | 5 | 2007 | 129 | 0.310 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 438 | 0.290 |
Why?
|
| Female | 38 | 2021 | 38015 | 0.290 |
Why?
|
| Risk Factors | 7 | 2022 | 5719 | 0.290 |
Why?
|
| Rheumatoid Factor | 2 | 2020 | 21 | 0.290 |
Why?
|
| Male | 35 | 2021 | 37281 | 0.280 |
Why?
|
| Decision Making | 1 | 2010 | 410 | 0.280 |
Why?
|
| Registries | 4 | 2018 | 730 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 929 | 0.270 |
Why?
|
| Prednisone | 2 | 2022 | 104 | 0.250 |
Why?
|
| Raynaud Disease | 2 | 2014 | 24 | 0.250 |
Why?
|
| Aged | 19 | 2021 | 14842 | 0.250 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2007 | 117 | 0.240 |
Why?
|
| United States | 7 | 2022 | 7335 | 0.240 |
Why?
|
| Follow-Up Studies | 6 | 2022 | 3256 | 0.240 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2003 | 10 | 0.240 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2003 | 11 | 0.240 |
Why?
|
| Accreditation | 2 | 2022 | 72 | 0.230 |
Why?
|
| Joints | 2 | 2007 | 30 | 0.230 |
Why?
|
| Cohort Studies | 4 | 2022 | 2356 | 0.230 |
Why?
|
| Program Evaluation | 2 | 2016 | 502 | 0.220 |
Why?
|
| Proteinuria | 1 | 2003 | 136 | 0.220 |
Why?
|
| Tomography | 1 | 2002 | 9 | 0.210 |
Why?
|
| Etanercept | 1 | 2021 | 12 | 0.210 |
Why?
|
| Adalimumab | 1 | 2021 | 16 | 0.210 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2002 | 31 | 0.210 |
Why?
|
| Feedback | 1 | 2022 | 90 | 0.210 |
Why?
|
| Optics and Photonics | 1 | 2002 | 29 | 0.210 |
Why?
|
| Hemosiderosis | 1 | 2021 | 7 | 0.210 |
Why?
|
| Methotrexate | 1 | 2022 | 91 | 0.200 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2021 | 12 | 0.200 |
Why?
|
| Sleep Wake Disorders | 1 | 2022 | 94 | 0.200 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 3 | 1996 | 24 | 0.200 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 114 | 0.200 |
Why?
|
| Secondary Prevention | 1 | 2022 | 291 | 0.200 |
Why?
|
| Chronic Periodontitis | 1 | 2021 | 18 | 0.200 |
Why?
|
| Severity of Illness Index | 8 | 2020 | 1851 | 0.200 |
Why?
|
| Bone and Bones | 1 | 2002 | 145 | 0.200 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 4 | 0.200 |
Why?
|
| Personnel Selection | 1 | 2021 | 37 | 0.190 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 172 | 0.190 |
Why?
|
| Physicians, Women | 1 | 2020 | 23 | 0.190 |
Why?
|
| Career Mobility | 1 | 2020 | 34 | 0.190 |
Why?
|
| Musculoskeletal System | 1 | 2020 | 11 | 0.190 |
Why?
|
| Needs Assessment | 2 | 2020 | 185 | 0.190 |
Why?
|
| Gout | 1 | 2020 | 9 | 0.190 |
Why?
|
| Tramadol | 1 | 2020 | 3 | 0.190 |
Why?
|
| Immunosuppressive Agents | 4 | 2007 | 514 | 0.180 |
Why?
|
| Learning | 1 | 2022 | 186 | 0.180 |
Why?
|
| Lovastatin | 1 | 2020 | 78 | 0.180 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 333 | 0.180 |
Why?
|
| Catastrophization | 1 | 2019 | 4 | 0.180 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 329 | 0.180 |
Why?
|
| Calcinosis | 1 | 2021 | 241 | 0.180 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 286 | 0.180 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 79 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 151 | 0.180 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 365 | 0.180 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 180 | 0.180 |
Why?
|
| Antigens, CD | 1 | 2020 | 230 | 0.170 |
Why?
|
| Treatment Outcome | 9 | 2021 | 7028 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 226 | 0.170 |
Why?
|
| Chronic Pain | 1 | 2020 | 110 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 212 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2020 | 453 | 0.160 |
Why?
|
| Pain Perception | 1 | 2018 | 22 | 0.160 |
Why?
|
| Goals | 2 | 2020 | 65 | 0.160 |
Why?
|
| Teriparatide | 1 | 2017 | 7 | 0.160 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 30 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 77 | 0.150 |
Why?
|
| Scleroderma, Diffuse | 2 | 2014 | 25 | 0.150 |
Why?
|
| Prospective Studies | 7 | 2019 | 3702 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2016 | 101 | 0.140 |
Why?
|
| Systemic Vasculitis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Biopsy, Needle | 2 | 2009 | 191 | 0.140 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2016 | 5 | 0.140 |
Why?
|
| Giant Cell Arteritis | 1 | 2016 | 10 | 0.140 |
Why?
|
| Myositis | 1 | 2016 | 24 | 0.140 |
Why?
|
| Self-Assessment | 1 | 2016 | 69 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 805 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 2016 | 77 | 0.130 |
Why?
|
| Vitamins | 1 | 2016 | 134 | 0.130 |
Why?
|
| Expert Testimony | 1 | 2015 | 47 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2016 | 248 | 0.130 |
Why?
|
| Certification | 1 | 2015 | 66 | 0.130 |
Why?
|
| Scleroderma, Limited | 1 | 2014 | 5 | 0.130 |
Why?
|
| Brassica | 1 | 1994 | 13 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2016 | 94 | 0.130 |
Why?
|
| Plant Oils | 1 | 1994 | 31 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2017 | 403 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 938 | 0.130 |
Why?
|
| Disease Progression | 3 | 2020 | 1037 | 0.120 |
Why?
|
| Data Collection | 1 | 2015 | 420 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2016 | 331 | 0.110 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2013 | 4 | 0.110 |
Why?
|
| Apoptosis | 1 | 2020 | 1640 | 0.110 |
Why?
|
| Double-Blind Method | 5 | 2020 | 1737 | 0.110 |
Why?
|
| Vital Capacity | 4 | 2018 | 43 | 0.110 |
Why?
|
| Femoral Fractures | 1 | 2013 | 45 | 0.110 |
Why?
|
| Cytokines | 1 | 1997 | 866 | 0.110 |
Why?
|
| Hospitalization | 1 | 2018 | 977 | 0.110 |
Why?
|
| Scleroderma, Localized | 2 | 2009 | 19 | 0.110 |
Why?
|
| Calcium | 1 | 2016 | 929 | 0.100 |
Why?
|
| Lung | 2 | 2014 | 849 | 0.100 |
Why?
|
| Vitamin D | 1 | 2016 | 516 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2003 | 648 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 2264 | 0.100 |
Why?
|
| Critical Pathways | 1 | 2010 | 33 | 0.100 |
Why?
|
| Fractures, Compression | 1 | 2010 | 11 | 0.090 |
Why?
|
| Selection Bias | 1 | 2010 | 23 | 0.090 |
Why?
|
| Hemodynamics | 3 | 2016 | 705 | 0.090 |
Why?
|
| Spinal Fractures | 1 | 2010 | 43 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2012 | 323 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 756 | 0.090 |
Why?
|
| Anesthetics, Local | 1 | 2010 | 83 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2014 | 1054 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2007 | 94 | 0.080 |
Why?
|
| Antihypertensive Agents | 2 | 2003 | 497 | 0.080 |
Why?
|
| Eosinophils | 1 | 2007 | 60 | 0.080 |
Why?
|
| Neutrophils | 1 | 2007 | 204 | 0.070 |
Why?
|
| Tryptophan | 2 | 1996 | 65 | 0.070 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2007 | 140 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2003 | 1139 | 0.070 |
Why?
|
| Sex Factors | 2 | 2020 | 1265 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2012 | 1447 | 0.070 |
Why?
|
| Inflammation | 2 | 2022 | 1030 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2798 | 0.060 |
Why?
|
| Animals | 4 | 2017 | 20877 | 0.060 |
Why?
|
| Respiratory Function Tests | 3 | 2012 | 123 | 0.060 |
Why?
|
| Young Adult | 2 | 2020 | 5708 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 107 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2006 | 434 | 0.060 |
Why?
|
| Pregnancy, High-Risk | 1 | 2003 | 14 | 0.060 |
Why?
|
| Hypertension, Renal | 1 | 2003 | 29 | 0.060 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2003 | 58 | 0.060 |
Why?
|
| Incidence | 1 | 2007 | 1582 | 0.060 |
Why?
|
| Fetal Death | 1 | 2003 | 49 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2003 | 99 | 0.060 |
Why?
|
| Quality of Life | 3 | 2007 | 1515 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 1046 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1860 | 0.050 |
Why?
|
| Absorption | 1 | 2002 | 49 | 0.050 |
Why?
|
| Gingival Crevicular Fluid | 1 | 2021 | 9 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2021 | 249 | 0.050 |
Why?
|
| Intubation | 1 | 2020 | 20 | 0.050 |
Why?
|
| Videoconferencing | 1 | 2021 | 43 | 0.050 |
Why?
|
| Boston | 1 | 2020 | 35 | 0.050 |
Why?
|
| Chickens | 1 | 2002 | 232 | 0.050 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2020 | 2 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 1174 | 0.050 |
Why?
|
| Pre-Eclampsia | 1 | 2003 | 202 | 0.050 |
Why?
|
| Workplace | 1 | 2021 | 75 | 0.050 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 24 | 0.050 |
Why?
|
| Epoprostenol | 1 | 2000 | 71 | 0.050 |
Why?
|
| Gout Suppressants | 1 | 2020 | 7 | 0.050 |
Why?
|
| Electronics | 1 | 2020 | 25 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2020 | 216 | 0.050 |
Why?
|
| Saliva | 1 | 2021 | 142 | 0.050 |
Why?
|
| Uric Acid | 1 | 2020 | 37 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2021 | 392 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 152 | 0.040 |
Why?
|
| Skin | 1 | 2003 | 451 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2323 | 0.040 |
Why?
|
| Leadership | 1 | 2020 | 135 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2002 | 384 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 521 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2018 | 46 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 371 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 880 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2002 | 689 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2018 | 64 | 0.040 |
Why?
|
| Ulna | 1 | 2017 | 2 | 0.040 |
Why?
|
| Radius | 1 | 2017 | 10 | 0.040 |
Why?
|
| Metacarpophalangeal Joint | 1 | 2017 | 8 | 0.040 |
Why?
|
| Depression | 1 | 2005 | 942 | 0.040 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 1997 | 3 | 0.040 |
Why?
|
| Chemokine CCL4 | 1 | 1997 | 6 | 0.040 |
Why?
|
| Chemokine CCL3 | 1 | 1997 | 9 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 1997 | 23 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2003 | 2004 | 0.040 |
Why?
|
| Pregnancy | 1 | 2003 | 2331 | 0.040 |
Why?
|
| Forecasting | 1 | 2018 | 277 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 1419 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 791 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2007 | 411 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1341 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 507 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1055 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 4843 | 0.030 |
Why?
|
| Echocardiography | 1 | 2018 | 515 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 4655 | 0.030 |
Why?
|
| CREST Syndrome | 1 | 1995 | 5 | 0.030 |
Why?
|
| Connective Tissue Diseases | 1 | 1995 | 18 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2014 | 12 | 0.030 |
Why?
|
| Hospitals, University | 2 | 2006 | 169 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 1994 | 29 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 2077 | 0.030 |
Why?
|
| Fingers | 1 | 1995 | 39 | 0.030 |
Why?
|
| Total Lung Capacity | 2 | 2007 | 14 | 0.030 |
Why?
|
| Cardiac Catheterization | 2 | 2012 | 419 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 626 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 498 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2014 | 25 | 0.030 |
Why?
|
| Syndrome | 1 | 1994 | 255 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2016 | 483 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2015 | 254 | 0.030 |
Why?
|
| Exercise Test | 1 | 2014 | 242 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 1996 | 342 | 0.030 |
Why?
|
| Osteomalacia | 1 | 2013 | 8 | 0.030 |
Why?
|
| South Carolina | 2 | 2013 | 2750 | 0.030 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2013 | 15 | 0.030 |
Why?
|
| Collagen | 1 | 1996 | 636 | 0.030 |
Why?
|
| Bone Nails | 1 | 2013 | 32 | 0.030 |
Why?
|
| Motor Activity | 1 | 1996 | 621 | 0.030 |
Why?
|
| North Carolina | 1 | 2013 | 224 | 0.030 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 2013 | 33 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 563 | 0.030 |
Why?
|
| Cognition | 1 | 1996 | 512 | 0.030 |
Why?
|
| Program Development | 1 | 2013 | 240 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2013 | 413 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2007 | 87 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2007 | 15 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 57 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 7264 | 0.020 |
Why?
|
| Leukopenia | 1 | 2006 | 23 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2007 | 117 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 567 | 0.020 |
Why?
|
| Age of Onset | 1 | 2006 | 188 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2007 | 298 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2006 | 737 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 2222 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 429 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2000 | 87 | 0.010 |
Why?
|
| Cardiac Output | 1 | 2000 | 133 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 334 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2000 | 102 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1996 | 2790 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1996 | 2550 | 0.010 |
Why?
|
| Swimming | 1 | 1996 | 38 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1996 | 189 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 201 | 0.010 |
Why?
|
| Maze Learning | 1 | 1996 | 138 | 0.010 |
Why?
|
| Reaction Time | 1 | 1996 | 170 | 0.010 |
Why?
|
| Body Weight | 1 | 1996 | 554 | 0.010 |
Why?
|
| Mice | 2 | 1996 | 8472 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1996 | 1039 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1997 | 307 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1996 | 1663 | 0.010 |
Why?
|
| Prognosis | 1 | 1997 | 2093 | 0.010 |
Why?
|